Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2022-05-29 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于股份回购实施结果暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement about the company's stock repurchase activities, including historical repurchase data, implementation results, and share cancellation details. It specifically discusses the completion of a share buyback program, the number of shares repurchased, prices, and the impact on the company's total share capital. There is no financial statement or earnings data presented, nor is it a report or presentation. The content fits the description of a 'Transaction in Own Shares' filing, which reports on the company's buyback or sale of its own shares.
2022-05-29 Chinese
天士力关于控股子公司注射用重组人尿激酶原增加急性缺血性脑卒中新适应症注册进展的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the withdrawal of a new drug indication registration application and related regulatory progress. It includes details about the drug, regulatory body (National Medical Products Administration), and the impact on the company. The document is short (1331 characters) and does not contain financial statements or detailed financial data. It is an official announcement regarding regulatory progress and risk disclosure, not a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-05-13 Chinese
天士力关于股份回购进展情况的公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement from the company regarding the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and references previous announcements and regulatory requirements for disclosure. The document is short (1004 characters) and focuses on the status update of share buybacks rather than financial results or other report types. This fits the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back or selling its own shares.
2022-05-06 Chinese
控股股东及实际控制人关于对天士力医药集团股份有限公司股票交易异常波动的书面回函
Regulatory Filings Classification · 95% confidence The document is a written response from the controlling shareholder regarding an inquiry about abnormal stock trading fluctuations. It explicitly states that no major undisclosed events affecting stock price occurred and denies any trading activity by the controlling shareholder during the period. The content is a regulatory response related to stock trading behavior and disclosure compliance, not a financial report, earnings release, or management discussion. It is a regulatory announcement addressing stock trading irregularities, fitting best under Regulatory Filings (RNS). The document is short (439 characters) and does not contain financial data or report content.
2022-04-28 Chinese
天士力股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is titled '股票交易异常波动公告' which translates to 'Stock Trading Abnormal Fluctuation Announcement'. It discusses the abnormal price fluctuations of the company's stock over three consecutive trading days and confirms that no undisclosed material information exists that could explain the price movement. The document includes statements from the board and related parties, risk warnings, and references to regulatory compliance with the Shanghai Stock Exchange rules. The document length is 1678 characters, which is relatively short and primarily serves as an announcement regarding stock price volatility rather than a financial report or detailed analysis. It does not contain financial statements or detailed management discussion. Therefore, it fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-04-28 Chinese
天士力关于股份回购进展情况的公告
Transaction in Own Shares Classification · 95% confidence The document is titled as an announcement regarding the progress of a share repurchase (股份回购进展情况的公告). It details the number of shares repurchased, the price range, total amount spent, and references previous related announcements. The content focuses on the company's share buyback activities and updates investors on the status of this capital action. It does not contain financial statements or detailed financial analysis, but rather an update on capital structure changes. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear and specific content about share repurchase progress.
2022-04-26 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.